Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
19 Apr 2023
First Patient Recruited to Cohort 3 of ACCENT Trial
11 Apr 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
28 Feb 2023
ACCENT Trial Recruitment Progress
23 Feb 2023
ATX - US Conference Presentation
09 Feb 2023
AmpliaTherapeutics - Lorne Cancer Conference Presentation
01 Feb 2023
First Patient Recruited to Cohort 2 of Accent Trial
30 Jan 2023
Quarterly Activities and Cashflow Reports - December 2022
11 Jan 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Previous
1
2
3
4
